Trial Profile
A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Blepharitis
- Focus Registrational; Therapeutic Use
- Acronyms ISV-305
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 24 Jun 2020 Status changed from active, no longer recruiting to completed.
- 15 May 2020 Planned End Date changed from 1 Aug 2020 to 1 Sep 2020.
- 19 Mar 2020 Planned End Date changed from 1 Apr 2020 to 1 Aug 2020.